Future of Sex
tagline
  • Remote Sex
  • Virtual Sex & Entertainment
  • Robots
  • Human Augmentation
  • Sex Tech
  • Dating & Relationships
  • Bizarre Bazaar 18+
  • Future of Sex Community
  • Remote Sex
  • Virtual Sex & Entertainment
  • Robots
  • Human Augmentation
  • Sex Tech
  • Dating & Relationships
  • Bizarre Bazaar 18+
  • Future of Sex Community
  • Designers Unveil Wildly Creative Fashions for Pandemic Living

  • This Stroker Gives Female-like Orgasms to Trans People and Men

  • Lora DiCarlo Responds to WOW Tech Group’s ‘Pleasure Air Technology’ Patent Claims

  • Sex Tech in 2021: What Industry Leaders Expect in the Year Ahead

  • VDOM’s ‘Cyber Penis’ Evolves Wearable Sex Tech for All Genders

  • When Will Male Sex Toys Go Mainstream?

  • The ‘Virtual Girlfriend’ Experience: AI Love Doll Sends Racy Pics and Texts

  • Touching Issues: Are COVID-19 Virtual Relationships Doomed to Fail?

Future of Sex is supported by our readers. When you buy through links on our site, we may earn an affiliate commission.

Home > Augmentation > Women’s Low Libido Drugs Sold Off by Pharma Company

Augmentation
Home›Augmentation›Women’s Low Libido Drugs Sold Off by Pharma Company

Women’s Low Libido Drugs Sold Off by Pharma Company

By Natasha Turner
February 5, 2020
1062
0

Exploring the fate of controversial medications intended as “female viagra.”

Last month, US-headquartered pharmaceutical company AMAG announced it would be selling off two of its women’s healthcare products, Intrarosa and Vyleesi.

Intrarosa, a brand name for prasterone, is a prescribed vaginal insert used by women in menopause to treat pain during vaginal intercourse. Vylessi, otherwise known as bremelanotide, is a prescribed injection that can be used to treat hypoactive sexual desire disorder in premenopausal women.

Vyleesi—sometimes referred to as “female viagra”—received Food and Drug Administration (FDA) approval in June last year. 

“There are women who, for no known reason, have reduced sexual desire that causes marked distress, and who can benefit from safe and effective pharmacologic treatment,” Hylton Joffe, director of the Center for Drug Evaluation and Research’s Division of Bone, Reproductive and Urologic Products, said in an FDA statement at the time.

But the decision was not without controversy. 

The Washington Post reported the FDA approved the drug without putting together an advisory panel to properly analyze it. Some experts criticized the over-medication of women’s sexual desire situations, which may also be a result of lifestyle and psychological factors. 

And commentators noted Vyleesi’s underwhelming results, perhaps in part related to the myriad of factors influencing women’s sexual desire. This is in contrast to viagra’s more simplistic solution to erectile dysfunction.

Despite this, Vyleesi was largely seen as an upgrade from its predecessor, Addyi. It reported fewer side effects and, as an injection, is in many cases more manageable than ingesting a daily pill. 

In its statement last month, AMAG chief executive William Heiden said, “We continue to believe in the significant long-term potential of Intrarosa and Vyleesi.” AMAG has yet to disclose Vyleesi’s revenue contributions.

So why sell?

In August 2019, US hedge fund Caligan Partners acquired 10.3% of AMAG’s shares, making it one of the pharmaceutical’s largest stakeholders. It began to suggest changes to AMAG that initially unsettled the pharmaceutical company’s leadership. 

In September AMAG sent a letter to its shareholders, urging them to reject Caligan’s plans to appoint new board members.

Days later Caligan Partners addressed AMAG shareholders with a letter of its own stating AMAG’s incumbent directors had ‘overseen the loss of vast sums of shareholder wealth’ and urging them to accept Caligan’s proposal for four nominees to the board.

A month later AMAG announced a settlement agreement that saw two new directors, suggested by Caligan, appointed, expanding the board to 11 directors until the 2020 annual meeting.

The decision announced last month to divest Intrarosa and Vyleesi (as well as for Heiden to step down) came as a result of a strategic review, assisted by AMAG’s financial advisor Goldman Sachs. This review was also called for by Caligan Partners.

The statement said selling off the two drugs would help keep down operational costs for the company, particularly as it hangs on to preterm birth medicine Makena, which an FDA advisory committee has recommended be pulled from the market. 

Caligan Partners is often cited as an activist hedge fund—a fund that makes a large enough investment in a company to be able to participate in its management. In the Harvard Business Review Martin Prosperity Institute director Roger Martin called activist hedge funds “utterly reviled by CEOs” and their performance “ambiguous”.

In this case, AMAG’s shares had fallen 25% last year to 3 September close, with Caligan co-founder David Johnson calling it undervalued and suggesting it needed “urgent change” to “reverse the sharp share price decline caused by the company’s misguided strategic priorities.”

What will happen to Vyleesi?

In last month’s statement, AMAG referenced interest in Intrarosa and Vyleesi. ‘The Company has received preliminary expressions of interest to acquire/sub-license the rights to these products,’ it said.

Heiden added: “The Company is seeking a transaction with a party that can make the investments necessary to maximize the value of these two important women’s healthcare products.”

Most recently, Palatin, the pharmaceutical company that exclusively licenses Vyleesi to AMAG for North America, has said it will ensure the next owner is “committed to the robust commercialization of the product”.

Conversations about women’s sexual health are important. And some medical professionals applauded the FDA approval of Vyleesi at least for recognizing and prioritizing women’s sexual health. 

The sell-off prompts discussion about Vyleesi, and women’s sexual health in general, inviting new buyer perspectives on a drug for which the jury is still out and reigniting the debate about the medication of women’s complicated libido patterns.

Image sources: Jhair Arcia, meaduva

Natasha Turner

Natasha Turner is a UK-based freelance journalist and editor interested in economic equality. She previously worked at Citywire where she launched and edited a publication focused on diversity in financial services, and gets excited when the worlds of finance and sex tech collide.
Previous Article

Sex Tech Hacker qDot Combines Video Games ...

Next Article

Planned Parenthood Is Battling Sexual Ignorance with ...

Related articles More from author

  • Artificial Womb
    Augmentation

    Exogenesis: How Artificial Wombs Might Change Sex and Procreation

    January 8, 2020
    By M. Christian
  • Augmentation

    1st Baby Born from Deceased Donor’s Womb Turns 1 Year Old! ??

    December 20, 2018
    By Tom Woodley
  • Augmentation

    Fertility Fears Drive Boom in #StayAtHome Sperm Collection

    July 21, 2020
    By M. Christian
  • Designers Off the Rack with Pandemic Fashions
    AugmentationSex Tech

    Designers Unveil Wildly Creative Fashions for Pandemic Living

    January 17, 2021
    By M. Christian
  • Augmentation

    Lesbian Couples Can Skip the Doctor’s Office Thanks to Ejaculating Strap-on Dildo

    April 25, 2017
    By Natasha Turner
  • Augmentation

    Neural Headsets Can Align Your Brainwaves with Your Lover’s

    November 16, 2015
    By Jenna Owsianik, Editor-in-Chief of FutureofSex.net

  • Sex Tech

    Finding the Pulse of Penis Pleasure

  • Remote Sex

    RealTouch Can Bring the Teledildonics Conjugal Visit to Reality

  • Sex Tech

    The Future Is Female: Can Women Save the Sex Tech Industry?

  • TOP REVIEWS

  • Realistic Sex Games

    Review of the Best Most Realistic Sex Games You Can Play [UPDATED]

    0
  • Multiplayer Online Sex Games

    Review of the Best Massively Multiplayer Online Sex Games

    0
  • Sex Games for Mac

    The Best Sex Games for Mac

    0
  • Best Sex Game Apps for Couples

    The Best Sex Game Apps for Couples for 2020 [Updated]

    0
  • The Best RPG Sex Games of 2020

    0

Like Us on Facebook

Latest Tweets

  • "Last year showed how important it is to maintain health and emotional balance and it couldn't be a better time to… https://t.co/9lAnFDeCMl

    4 hours ago
  • Wildly creative designers unveil unique and outlandish fashions made to keep you safe while still getting your haut… https://t.co/J6MHqmrhF7

    11 hours ago
  • The new Ion stroker from @Arcwaveofficial excites pleasure receptors in the frenulum to give the sensation of femal… https://t.co/r6DjPo3Flr

    15 hours ago
  • In a press statement, @LoraDiCarlo_HQ denies claims of patent infringement, alleging the aim of WOW Tech Group's la… https://t.co/9en8yormEy

    Jan 16, 2021
  • Expert insights on #sextech in 2021: *Jeff Bennett/@MedicalMorari *Dema Tio/@Vibease *Angelina Aleksandrovich/… https://t.co/xK2Sm1VY1u

    Jan 15, 2021
Follow @futureofsex

Follow us

  • Home
  • About
  • ADVERTISE
  • Contribute
  • Story Ideas?
  • Sitemap
  • Privacy Policy
  • Terms and Conditions
© 2011 - 2020 Future Exploration Network
This website or its third-party tools use cookies to improve user experience and track affiliate sales. To learn more about why we need to use cookies, please refer to the Privacy Policy.

By clicking the agree button or continuing to browse through the website, you agree to the use of cookies. Accept Privacy Policy
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary